Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Predictive Oncology Inc (POAI)

Predictive Oncology Inc (POAI)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 11,289
  • Shares Outstanding, K 3,925
  • Annual Sales, $ 1,410 K
  • Annual Income, $ -10,090 K
  • 60-Month Beta 2.32
  • Price/Sales 7.56
  • Price/Cash Flow N/A
  • Price/Book 0.50

Price Performance

See More
Period Period Low Period High Performance
1-Month
2.35 +22.39%
on 12/04/19
4.68 -38.54%
on 11/14/19
-1.05 (-26.72%)
since 11/13/19
3-Month
2.35 +22.39%
on 12/04/19
6.25 -53.98%
on 09/30/19
-2.52 (-46.74%)
since 09/13/19
52-Week
2.35 +22.39%
on 12/04/19
11.50 -74.99%
on 02/05/19
-4.62 (-61.65%)
since 12/13/18

Most Recent Stories

More News
Predictive Oncology Confirms Indications of Interest for Skyline Medical Business

Predictive Oncology Inc. (NASDAQ: POAI) ("Predictive Oncology" or "the Company"), focused on applying artificial intelligence ("AI") to personalized medicine and drug discovery, today announced that it...

SKLN : 1.21 (-11.03%)
POAI : 2.88 (+5.74%)
New Hope in the Battle Against Ovarian Cancer

Despite the enormous progress made in the war against cancers, ovarian cancer has proved to be a tenacious foe. Progress is being made, however, as AI predictive models are being used to better target...

RHHBY : 38.1600 (-0.73%)
GSK : 45.98 (+0.11%)
AZN : 48.36 (+0.92%)
BMY : 63.82 (-0.19%)
POAI : 2.88 (+5.74%)
Delivering Precision Medicine's True Potential: Big Data, Artificial Intelligence Identify New Cancer Therapeutics

The field of precision medicine has latched upon what may well be the Holy Grail in the fight against cancer. When big data are utilized by teams of pathologists, data can be incredibly helpful, but when...

HGRL : 0.3000 (-14.29%)
RHHBY : 38.1600 (-0.73%)
GSK : 45.98 (+0.11%)
AZN : 48.36 (+0.92%)
BMY : 63.82 (-0.19%)
POAI : 2.88 (+5.74%)
Skyline Medical, a Division of Predictive Oncology Inc. (POAI), Sells 10 STREAMWAY(R) Systems to Prominent Teaching Hospital

-- Skyline Medical, a subsidiary of POAI, continues to forge the standardization of waste fluid management with its sale of 10 systems in Rochester, NY.

SKLN : 1.21 (-11.03%)
POAI : 2.88 (+5.74%)
Predictive Oncology Inc. (POAI) Sells 10 STREAMWAY(R) Systems to Prominent Teaching Hospital

-- Skyline Medical, a subsidiary of POAI, continues to forge the standardization of waste fluid management with its sale of 10 systems in Rochester, NY.

SKLN : 1.21 (-11.03%)
POAI : 2.88 (+5.74%)
Predictive Oncology Inc. Reports Second Quarter 2019 Financial Results and Provides Corporate Update

Predictive Oncology Inc., (NASDAQ: POAI) ("Predictive Oncology " or "the Company") an artificial intelligence (AI) and data-driven functional precision medicine company with the mission of improving the...

IDXG : 0.45 (unch)
POAI : 2.88 (+5.74%)
Predictive Oncology Subsidiary Helomics Executes Next Phase of Agreement with Interpace to Enhance the Diagnosis of Thyroid Cancer via AI-Driven Models

Predictive Oncology (Nasdaq: POAI) ("Predictive Oncology" or "the Company"), a company focused on applying artificial intelligence to personalized medicine and drug discovery, announced today its Helomics...

IDXG : 0.45 (unch)
POAI : 2.88 (+5.74%)
Interpace Diagnostics Enters Agreement with Predictive Oncology to Enhance Diagnosis of Thyroid Cancer Via AI-Driven Analysis

Interpace Diagnostics Group, Inc. (NASDAQ: IDXG) ("Interpace" or the "Company), announced today that it has executed an agreement with the Helomics division of Predictive Oncology (NASDAQ: POAI), a company...

IDXG : 0.45 (unch)
POAI : 2.88 (+5.74%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Trade POAI with:

Business Summary

Predictive Oncology Inc. is focused on applying artificial intelligence to personalized medicine and drug discovery. Its operating business unit consists of Helomics, TumorGenesis and Skyline Medical. Predictive Oncology Inc., formerly known as Precision Therapeutics Inc., is based in MINNEAPOLIS.

See More

Key Turning Points

2nd Resistance Point 3.14
1st Resistance Point 3.01
Last Price 2.88
1st Support Level 2.80
2nd Support Level 2.72

See More

52-Week High 11.50
Fibonacci 61.8% 8.00
Fibonacci 50% 6.93
Fibonacci 38.2% 5.85
Last Price 2.88
52-Week Low 2.35

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar